Gillette
This article was originally published in The Rose Sheet
Executive Summary
Massachusetts Secretary of the Commonwealth William Galvin issues subpoenas ad testificandum to several Gillette employees on May 11 to testify in connection with the state Securities Division's investigation of Procter & Gamble's acquisition of the razor manufacturer. Among those subpoenaed to testify later this month are Gillette CFO Charles Cramb, Board of Directors Vice Chairman Edward Degraan and Human Resources Manager Edward Guillet. Galvin has been investigating the merger since February, shortly after it was announced (1"The Rose Sheet" Feb. 7, 2005, p. 8). Gillette has resisted previous subpoenas issued by Galvin, recently requesting a Suffolk Superior Court quash a request for additional documents pertaining to the merger. The court ruled in favor of Gillette April 28 (2"The Rose Sheet" May 9, 2005, p. 7)...
You may also be interested in...
Gillette
Massachusetts Secretary of the Commonwealth William Galvin subpoena Gillette President & CEO James Kilts to testify June 1 regarding fairness opinions generated by Goldman, Sachs & Co. and UBS Securities in connection with the firm's acquisition by Procter & Gamble. Galvin also issues May 19 subpoenas al testificandum to Goldman Sachs employees Jack Levy and Stephan Feldgoise and UBS Securities' Richard Case and Blair Effron relating to fairness opinions provided by the firms. Galvin previously issued subpoenaes to Gillette employees in connection with the acquisition, which he has been investigating since February (1"The Rose Sheet" May 16, 2005, In Brief and 2"The Rose Sheet" Feb. 7, 2005, p. 8)...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.